Growth hormone suppression after a glucose challenge: why one resting result cannot replace the curve
A suppression test asks whether a hormone changes in response to a defined challenge.

A suppression test asks whether a hormone changes in response to a defined challenge. This study registered the proportion reaching a particular growth hormone suppression threshold, with repeated sampling around the test. A single resting hormone value cannot recreate the sequence of observations.
A threshold crossing is different from an average
A threshold creates a yes-or-no classification for each person under the protocol. A group percentage then counts those classifications; it is not the average hormone concentration. Interpreting a clinical test requires an appropriate assay, sampling schedule, reason for testing and specialist judgment. A package labelled in international units has no numerical relationship to the proportion that crosses a study threshold. Do not compare those numbers simply because both appear in searches for growth hormone.
Distinguish a response from a resting measurement
A single hormone result can look unremarkable without answering whether the concentration fell below a defined threshold after the glucose challenge. Ask for the sampling sequence and the laboratory units. A report showing only the lowest value still needs the test context before it can be compared with a research threshold.
A threshold also depends on the analytical method and the conditions under which samples were obtained. A laboratory using another assay may report a different reference framework. The threshold named in a research protocol should not be taken from the abstract and applied to an unrelated isolated result. The relevant clinical team can establish whether the original sampling and method are comparable.
Participant and measurement details
- People in the record: 28 (actual enrollment). Eligible ages: 18 years and older.
- Clinical setting: Acromegaly, Type 2 Diabetes Mellitus.
- Named study interventions: Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1, Placebo.
- Study design: interventional, non randomized, parallel. Masking: single.
- Measured here: The percentage meeting a defined growth hormone suppression threshold.
- Research locations listed in the record include: Los Angeles, United States.
- Study calendar in the registration: start 2008-12; primary completion 2013-08.
- Primary record: Cedars-Sinai Medical Center. ClinicalTrials.gov, NCT00915954.
The Somatropin presentation in Bali has a labelled activity per pen. It cannot reconstruct the timing of an oral glucose challenge. If a patient brings laboratory results, the sampling times and report are more useful than copying the largest or smallest hormone value into a chat.
